1Lehtovirta P, Apter D, STENMAN U H. Serum CA 125 Levels during the menstrual cycle. B JOG:An International Journal of Obstetrics & Gynaecology, 1990,97(10):930-933.
2段涛.妇产科程序诊断.第1版.上海:江苏科学技术出版社,2004:114-116.
3Yin B WT, Lloyd KO. Molecular Cloning of the CA 125 Ovarian Cancer Antigen IDENTIFICATION AS A NEW MVC16. Journal of Biological Chemistry, 2001,276(29):27371-27375.
4Wagner U, kuhler S, Reinartz S, et al. Immunological Consolidation of Ovarian carcinoma Recurrences with Monclonal Anti-ldiotype Antibody ACA125:Immune Responses and Survival in Palliative Treatment see The Biology Behind:KA Food and M. Bhattacharya- Chatterjee,2001,7(5): 1154-1162.
5Wagner U, Schlebusch H, kohler S, et al. Immunological responses to the Tumor-Associated Antigen CA 15 in Patients with Advanced Ovarian Cancer Induced by the Murine Monoclonal Anti-idiotype Vaccine ACA125. Hybridoma, 1997, 16(1):33-40.
6Wong NK, RL, Panico M, et al. Characterizatien of the oligosaccharides associated with the human ovarian tumor maker CA 125. Journal of Biological Chemistry, 2003, 278(31):28619-28634.
7Bloeh B, et al.S Mr Med J, 1989, 76(12):670-671.
8Meden H, et 81. Int J Biol Markers, 1998,13:231-237.
9Nagele F, et al. Obstet Gynecol, 1995, 86:259-264.
10Rustin GJS, Bast RC Jr, et al. Clinical Cancer Research, 2004, 10:3919-3926.
2Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009 [J]. CA Cancer J Clin, 2009(59 ) : 225-249.
3Fader A N, Rose P G. Role of surgery in ovarian carcinoma Oncol, 2007( 25 ) : 2873-2883.
4Tian C, Markman M, Zaino R, et al. CA- 125 change after chemother- apy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study [J]. Cancer,2009,115(7): 1395-1403.
5Medeiros L R, Rosa D D, Da R M, et al. Accuracy of CA125 in the diagnosis of ovarian tumors: a quantitative systematic review [J]. Eur J Obstet Gynecol Reprod Biol,2009,142(2):99-105.
6Milojkovic M, Hrgovie Z, Hrgovie I, et al. Significance of CA125 sermn level in discrimination between benign and malignant masses in the DelvisI-J]. Arch Gvnecol Obstet.2004,269(3):176-180.
7Gemer O, Segal S, Kopmar A. Preoperative CA-125 level as a predic- tor of non optimal cytoredution of advanced epithelial ovarian cancer [J]. Aeta Ohstet Gynecol Scand, 2001,80(6) : 583-585.
8Kirehhoff C, Habben I, Lvell R,et al. A major human epididymis- specific cDNA Encodes a protein with sequence homology to extracellular proteinase inhibitors [J]. Biol Rep-rod, 1991,45(2):350-357.
9Sehummer M, Ng W V,Bumgarner R E, et al. Comparative hybridiza- tion of an array of 21,500 ovarian eDNAs for the discovery of genes over-expressed in ovarian car -cinomas[J]. Gene, 1999,238 (2) : 375-385.
10Drapkin R, Von Horsten H H, Lin Y, et al. Human epididymis pro- tein 4 (HE 4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carei-nomas[J]. Cancer Res, 2005,65 (6) : 2162- 2169.
